Tyler Jacks - Amgen Independent Director
| AMGN Stock | MXN 4,651 201.54 4.53% |
Director
Dr. Tyler Jacks Ph.D., is an Independent Director of the Company. Dr. Jack joined the faculty of Massachusetts Institute of Technology, or MIT, in 1992 and is currently the David H. Koch Professor of Biology and director of the David H. Koch Institute for Integrative Cancer Research, which brings together biologists and engineers to improve detection, diagnosis and treatment of cancer, a position he has held since 2007. Dr. Jacks was an investigator with the Howard Hughes Medical Institute, a nonprofit medical research organization, since 1994. Dr. Jacks was a director of Thermo Fisher Scientific, Inc., a life sciences supply company, since May 2009, and serves on its Strategy and Finance Committee and scientific advisory board. In 2006, he cofounded T2 Biosystems, Inc., a biotechnology company, and served on its scientific advisory board until 2013. Dr. Jacks was a consultant scientific advisor to Epizyme, Inc., a biopharmaceutical company, since 2007, and has served on the scientific advisory board of SQZ Biotech, a privatelyheld biotechnology company, since 2015. Dr. Jacks served on the scientific advisory board of Aveo Pharmaceuticals Inc., a biopharmaceutical company, from 2001 until 2013. In 2015, Dr. Jacks founded Dragonfly Therapeutics, Inc., a privatelyheld biopharmaceutical company, in 2015 and serves as coChair of its scientific advisory board since 2012.
| Age | 57 |
| Tenure | 12 years |
| Professional Marks | Ph.D |
| Phone | 805 447 1000 |
| Web | https://www.amgen.com |
Amgen Management Efficiency
The company has return on total asset (ROA) of 0.0997 % which means that it generated a profit of $0.0997 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 1.2647 %, meaning that it generated $1.2647 on every $100 dollars invested by stockholders. Amgen's management efficiency ratios could be used to measure how well Amgen manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Mary McCarthy | Micron Technology | 64 | |
| Pamela Joyner | First Republic Bank | 58 | |
| Lawrence Mondry | Micron Technology | 56 | |
| Zaka Mian | Lloyds Banking Group | N/A | |
| Shellye Archambeau | Verizon Communications | 55 | |
| Stuart Sinclair | Lloyds Banking Group | 63 | |
| Sara Weller | Lloyds Banking Group | 53 | |
| Melanie Healey | Verizon Communications | 56 | |
| Laura Peterson | Air Transport Services | 58 | |
| Juan Colombas | Lloyds Banking Group | N/A | |
| Gregory Wasson | Verizon Communications | 58 | |
| Melina Higgins | Genworth Financial | 50 | |
| Cheryl Spielman | First Republic Bank | 63 | |
| Christine Mead | Genworth Financial | 59 | |
| Kathy Waller | Delta Air Lines | 60 | |
| Martha Keeth | Verizon Communications | 71 | |
| Lynn Dugle | Micron Technology | 60 | |
| Clarence Otis | Verizon Communications | 61 | |
| James Lupton | Lloyds Banking Group | N/A | |
| Gabriel Shaheen | Steel Dynamics | 63 | |
| Nancy Karch | Genworth Financial | 67 | |
Management Performance
| Return On Equity | 1.26 | |||
| Return On Asset | 0.0997 |
Amgen Inc Leadership Team
Elected by the shareholders, the Amgen's board of directors comprises two types of representatives: Amgen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Amgen. The board's role is to monitor Amgen's management team and ensure that shareholders' interests are well served. Amgen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Amgen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Linda Louie, VP Officer | ||
| Frank Herringer, Independent Director | ||
| Nancy Grygiel, Sr Officer | ||
| Francois Carbonnel, Independent Director | ||
| Rebecca Henderson, Independent Director | ||
| Annette Such, Chief Accounting Officer | ||
| Sanders Williams, Independent Director | ||
| Vance Coffman, Lead Independent Director | ||
| David Reese, Executive Vice President - Research and Development | ||
| Tyler Jacks, Independent Director | ||
| Brian McNamee, Executive Vice President - Full Potential Initiatives | ||
| Gregory Garland, Independent Director | ||
| Charles Holley, Director | ||
| Esteban Santos, Executive Vice President Operations | ||
| Jonathan Graham, Senior Vice President General Counsel, Secretary | ||
| Sean Harper, Executive Vice President - Research and Development | ||
| Mike Zahigian, VP Officer | ||
| Ellen Kullman, Director | ||
| Frank Biondi, Independent Director | ||
| Arvind Sood, IR Contact Officer | ||
| David Meline, CFO and Executive VP | ||
| Ronald Sugar, Independent Director | ||
| Stuart Tross, Senior Vice President - Human Resources | ||
| Robert Bradway, Chairman, CEO and President Chairman of Executive Committee and Member of Equity Award Committee | ||
| Murdo Gordon, Executive Vice President of Global Commercial Operations | ||
| Peter Griffith, Ex CFO | ||
| Wanda Austin, Independent Director | ||
| Robert Eckert, Independent Director | ||
| Madhavan Balachandran, Executive VP of Operations | ||
| Lori Johnston, Senior Vice President - Human Resources | ||
| Brian Druker, Independent Director | ||
| Cynthia Patton, Senior Vice President Chief Compliance Officer | ||
| Greg Garland, Independent Director | ||
| Robert Williams, Independent Director | ||
| Judith Pelham, Independent Director | ||
| David Baltimore, Independent Director | ||
| Fred Hassan, Director | ||
| David Piacquad, Senior Vice President - Business Development | ||
| Anthony Hooper, Executive VP of Global Commercial Operations | ||
| David MD, Ex RD |
Amgen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Amgen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 1.26 | |||
| Return On Asset | 0.0997 | |||
| Profit Margin | 0.25 % | |||
| Operating Margin | 0.38 % | |||
| Current Valuation | 3.36 T | |||
| Shares Outstanding | 533.98 M | |||
| Shares Owned By Insiders | 0.20 % | |||
| Shares Owned By Institutions | 80.38 % | |||
| Price To Earning | 267.53 X | |||
| Price To Book | 40.33 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Amgen in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Amgen's short interest history, or implied volatility extrapolated from Amgen options trading.
Pair Trading with Amgen
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Amgen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Amgen will appreciate offsetting losses from the drop in the long position's value.Moving together with Amgen Stock
| 0.79 | ROGN | Roche Holding AG | PairCorr |
Moving against Amgen Stock
| 0.46 | TSMN | Taiwan Semiconductor | PairCorr |
| 0.45 | TMN | Toyota Motor | PairCorr |
The ability to find closely correlated positions to Amgen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Amgen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Amgen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Amgen Inc to buy it.
The correlation of Amgen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Amgen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Amgen Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Amgen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amgen Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Complementary Tools for Amgen Stock analysis
When running Amgen's price analysis, check to measure Amgen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amgen is operating at the current time. Most of Amgen's value examination focuses on studying past and present price action to predict the probability of Amgen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amgen's price. Additionally, you may evaluate how the addition of Amgen to your portfolios can decrease your overall portfolio volatility.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data |